pbm specialti headwind
highlight lack scale
dplo profit warn underscor rapid chang take
place specialti pharmaci pbm market place
highlight scale critic success factor reduc
ebitda lower pt
friday diplomat issu profit warn cite addit custom loss
pbm side well new challeng specialti market payer pbm
increasingli focus manag spend within prefer
initi strategi behind diplomat decis acquir pbm asset
attempt creat prefer network cross sell specialti
pharmaci servic howev combin increas competit among
pbm lower realiz profit opportun rebat side translat
increas pressur busi last month diplomat
announc sever larg loss million loss announc
call addit client loss total million announc januari
compani issu origin guidanc today announc
emphas issu contain client suggest broader
system issu note rebat risk specif call take
account pbm segment enterpris profit deriv
rebat see addit risk number rebat guarante
near-term potenti long-term chang hh drug
rebat propos go effect
deterior fundament specialti side repres new headwind
past prior manag diplomat acknowledg
increas pressur payer base today disclosur seem
challeng acceler like result recent industri consolid
takeout still tabl diplomat awar
potenti transact compani comment interest
 distribut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
potenti transact prior bull case took account takeout
scenario see still see valu diplomat specialti infus
asset largest independ specialti pharmaci entiti manag
 influenc larg patient popul medic specialti spend
lower estim reduc revenu estim
million vs million
previous reduc adj ebitda estim
million vs million previous
ep estim move
pbm estim reduc script growth estim
longer includ benefit base busi new busi growth
assum lower client retent assum revenue/script grow
in-lin estim inflat reduc
gross margin estim busi reflect lower profit
specialti estim reduc script growth
assumpt model growth script vs previous
base case price target previous repres upsid
last price bull case previous bear case
previous updat dcf base price target factor lower near-
long-term revenu ebitda growth lower termin growth vs
previous partial off-set lower wacc vs prior
read-thru compani coverag
diplomat distributor repres billion compani cog
lower specialti volum could headwind amerisourc top-lin
base case dcf includ termin growth wacc
ev/ebitda bull case ebitda
ev/ebitda bull case ebitda
higher contribut infus specialti drive long-term high-single-digit
revenu growth ebitda margin annual ebitda growth
high-single-digit dir fee declin
ev/ebitda base case ebitda
ev/ebitda base case ebitda
diversif strategi pbm infus specialti servic drive long-
term low singl digit revenu growth dir fees/reb guarante stabil
growth infus specialti servic drive ebitda margin
annual ebitda growth mid singl digit
ev/ebitda bear case ebitda
ev/ebitda bear case ebitda
diversif strategi see execut integr headwind revenu
growth slows/declin ebitda margin pressur increas dir
fees/reb guarante slower growth infus specialti servic
keep ebitda margin annual ebitda growth
last yr via seri acquisit
dplo diversifi end-to-end
infus center mail order pharmaci
high servic level model reson
biopharma manufactur patient
translat disproportion share
combin specialti pbm
increas leverag improv purchas
econom make pbm competit
pbm rebat exposur pro
forma ebitda add risk thesi face
loss addit pbm contract weigh
ep
given dplo lack scale believ
disadvantag
new limit distribut product
chang drug price inflat
risk achiev price
delay biopharmaceut pipelin
inabl target anticip synergi
reimburs risk dir fee
exclus narrow network
chang rebat polici
addit pbm contract loss
specialti pressur off-set
